Acura Pharmaceuticals, Inc.

ACUR

US00509L8028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 19:05:22 12/07/2024 BST			5-day change	1st Jan Change
0.02 ^USD	0.00%		-27.27%	+19,900.00%

06-14	Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	CI
06-04	Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announce Executive Changes	CI

Acura Pharmaceuticals Inc. Announces Resignation of David Azad as a Member of Board of Directors, Effective December 31, 2012

January 03, 2013 at 12:00 pm

Acura Pharmaceuticals Inc. announced that Mr. David Azad resigned as a member of Board of Directors, effective December 31, 2012.

Latest news about Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	06-13	CI
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announce Executive Changes	06-04	CI
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announces CFO Changes	06-04	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.075 million in funding	06-02	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	05-09	CI
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	03-26	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	03-13	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	02-14	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	02-13	CI
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	12-21	CI
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	25/09/23	CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	31/08/23	CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	30/08/23	CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	16/08/23	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	28/07/23	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/06/23	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	30/06/23	CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	29/06/23	CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	28/06/23	CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC	26/05/23	CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03	13/02/23	CI
Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03	02/02/23	CI
Acura Pharmaceuticals, Inc. announced that it has received $2.319279 million in funding from Abuse Deterrent Pharma, LLC	09/11/22	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	12/10/22	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from John Schutte	26/08/22	CI

Chart Acura Pharmaceuticals, Inc.

Duration

Period

More charts

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACURA PHARMACEUTICALS, INC.	+19,900.00%	1.33M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B